Search

Your search keyword '"Barshop, Kenneth"' showing total 47 results
Start Over Author "Barshop, Kenneth"
47 results on '"Barshop, Kenneth"'

5. Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center

Author

Eberly, Lauren A., Richterman, Aaron, Beckett, Anne G., Wispelwey, Bram, Marsh, Regan H., Cleveland Manchanda, Emily C., Chang, Cindy Y., Glynn, Robert J., Brooks, Katherine C., Boxer, Robert, Kakoza, Rose, Goldsmith, Jennifer, Loscalzo, Joseph, Morse, Michelle, Lewis, Eldrin F., Abel, Samantha, Adams, Ayrenne, Anaya, Joseph, Andrews, Erik H, Atkinson, Benjamin, Avutu, Viswatej, Bachorik, Alexandra, Badri, Omar, Bailey, Mariel, Baird, Katie, Bakshi, Salina, Balaban, Denis, Barshop, Kenneth, Baumrin, Emily, Bayomy, Omar, Beamesderfer, Julia, Becker, Nora, Berg, David D., Berman, Adam N., Blum, Steven M., Boardman, Alexander P., Boden, Kaeleen, Bonacci, Robert A, Brown, Sarah, Campbell, Kirsti, Case, Siobhan, Cetrone, Emily, Charrow, Alexandra, Chiang, David, Clark, Devin, Cohen, Aaron J., Cooper, Alissa, Cordova, Tomas, Cuneo, C. Nicholas, de Feria, Alsina Alejandro, Deffenbacher, Karen, DeFilippis, Ersilia M., DeGregorio, Geneva, Deutsch, Aaron J., Diephuis, Bradford, Divakaran, Sanjay, Dorschner, Peter, Downing, Nicholas, Drescher, Caitlin, D’Silva, Kristin M., Dunbar, Peter, Duong, David, Earp, Sarah, Eckhardt, Christine, Elman, Scott A., England, Ross, Everett, Kay, Fedotova, Natalie, Feingold-Link, Tamara, Ferreira, Mark, Fisher, Herrick, Foo, Patricia, Foote, Michael, Franco, Idalid, Gilliland, Thomas, Greb, Jacqueline, Greco, Katherine, Grewal, Sungat, Grin, Benjamin, Growdon, Matthew E., Guercio, Brendan, Hahn, Cynthia K., Hasselfeld, Brian, Haydu, Erika J, Hermes, Zachary, Hildick-Smith, Gordon, Holcomb, Zachary, Holroyd, Kathryn, Horton, Laura, Huang, George, Jablonski, Stanley, Jacobs, Douglas, Jain, Nina, Japa, Sohan, Joseph, Richard, Kalashnikova, Mariya, Kalwani, Neil, Kang, Daniel, Karan, Abraar, Katz, Joel T, Kellner, Daniel, Kidia, Khameer, Kim, June-Ho, Knowles, Scott M, Kolbe, Laura, Kore, Idil, Koullias, Yiannis, Kuye, Ifedayo, Lang, Joshua, Lawlor, Matthew, Lechner, Melissa G., Lee, Ken, Lee, Scott, Lee, Zachary, Limaye, Neha, Lin-Beckford, Stephanie, Lipsyc, Marla, Little, Jessica, Loewenthal, Julia, Logaraj, Ranjani, Lopez, Diana M, Loriaux, Daniel, Lu, Yi, Ma, Kevin, Marukian, Nareh, Matias, Wilfredo, Mayers, Jared R., McConnell, Ian, McLaughlin, Michael, Meade, Christina, Meador, Catherine, Mehta, Anish, Messenger, Elizabeth, Michaelidis, Constantinos, Mirsky, Jacob, Mitten, Emilie, Mueller, Alisa, Mullur, Jyotsna, Munir, Amir, Murphy, Emily, Nagami, Ellen, Natarajan, Abirami, Nsahlai, Michelle, Nze, Chijioke, Okwara, Noreen, Olds, Peter, Paez, Rafael, Pardo, Michael, Patel, Siddharth, Petersen, Alec, Phelan, Laura, Pimenta, Erica, Pipilas, Daniel, Plovanich, Molly, Pong, Denise, Powers, Brian W., Rao, Anita, Ramirez Batlle, Haiyan, Ramsis, Mattheus, Reichardt, Anna, Reiger, Sheridan, Rengarajan, Michelle, Rico, Stephanie, Rome, Benjamin N., Rosales, Rachael, Rotenstein, Lisa, Roy, Alexis, Royston, Sarah, Rozansky, Hallie, Rudder, Meghan, Ryan, Christine E., Salgado, Sanjay, Sanchez, Pablo, Schulte, Jennifer, Sekar, Aswin, Semenkovich, Nicholas, Shannon, Evan, Shaw, Neil, Shorten, Andrew Ben, Shrauner, William, Sinnenberg, Lauren, Smithy, James W., Snyder, Gregory, Sreekrishnan, Anirudh, Stabenau, Hans, Stavrou, Eleni, Stergachis, Andrew, Stern, Robert, Stone, Alexander, Tabrizi, Shervin, Tanyos, Sam, Thomas, Cristina, Thun, Haley, Torres-Lockhart, Kristine, Tran, An, Treasure, Carolyn, Tsai, Frederick D., Tsaur, Stephen, Tschirhart, Evan, Tuwatananurak, Justin, Venkateswaran, Ramkumar V., Vishnevetsky, Anastasia, Wahl, Lindsay, Wall, April, Wallace, Frances, Walsh, Elisa, Wang, Priscilla, Ward, Heather B., Warner, Lindsay N., Weeks, Lachelle D., Weiskopf, Kipp, Wengrod, Jordan, Williams, Jessica N., Winkler, Marisa, Wong, Jeffrey L., Worster, Devin, Wright, Aileen, Wunsch, Caroline, Wynter, Jamila S., Yarbrough, Chase, Yau, Wai-Ying, Yazdi, Daniel, Yeh, Jennifer, Yialamas, Maria A., Yozamp, Nicholas, Zambrotta, Marina, and Zon, Rebecca

Published
2019
Full Text
View/download PDF

45. The investigational drug camicinalfor the treatment of gastroparesis

Author

Barshop, Kenneth and Kuo, Braden

Abstract

Introduction:Gastroparesis is a syndrome of delayed gastric emptying in the absence of mechanical obstruction that presents with upper gastrointestinal symptoms. Despite its growing prevalence, there remains an unmet clinical need for more efficacious prokinetic treatment options. The current market includes prokinetic agents that reduce gastroparesis symptoms. However, adverse drug effects and tachyphylaxis with repeated dosing are among the factors that limit their use. Camicinal(GSK962040) is the most advanced, small-molecule, selective motilin receptor agonist with therapeutic potential to date.Areas covered:This article reviews the literature on the limitations of current prokinetic agents used in the treatment of gastroparesis. It also summarizes the current evidence and influential clinical trial results involving the investigational drug camicinal, and shares its preliminary findings from the literature.Expert opinion:Camicinal represents a new opportunity as a treatment in a clinical area in need of new agents. There is emerging literature to support how the drug addresses both gastroparesis symptoms and dysmotility with no significant adverse effects or tachyphylaxis reported to date. Challenges remain in getting a new compound approved for gastroparesis. However, careful design of future trials will help to continue the record of success camicinal trials have had thus far.

Published
2015
Full Text
View/download PDF

46. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation.

Author

Singh P, Staller K, Barshop K, Dai E, Newman J, Yoon S, Castel S, and Kuo B

Subjects
Activities of Daily Living, Adult, Analysis of Variance, Avoidance Learning, Boston, Chi-Square Distribution, Constipation diagnosis, Constipation etiology, Constipation physiopathology, Cost of Illness, Diarrhea diagnosis, Diarrhea etiology, Diarrhea physiopathology, Feeding Behavior, Female, Humans, Interpersonal Relations, Irritable Bowel Syndrome complications, Irritable Bowel Syndrome diagnosis, Irritable Bowel Syndrome physiopathology, Male, Middle Aged, Retrospective Studies, Risk Factors, Severity of Illness Index, Social Behavior, Surveys and Questionnaires, Tertiary Care Centers, Constipation psychology, Diarrhea psychology, Irritable Bowel Syndrome psychology, Quality of Life
Abstract

Aim: To determine effect of irritable bowel syndrome (IBS) subtype on IBS-specific quality of life (QOL) questionnaire and its subscales., Methods: We studied IBS patients visiting our functional gastroenterology disorder clinic at a tertiary care center of Unites States. IBS and IBS subtype were diagnosed using Rome-III questionnaire. QOL was assessed using IBS-QOL questionnaire. IBS-QOL assesses quality of life along eight subscales: dysphoria, interference with activities, body image, health worry, food avoidance, social reactions, sexual health, and effect on relationships. IBS-QOL and its subscales were both scored on a range of 0-100 with higher scores suggestive of better QOL. Results of overall IBS-QOL scores and subscale scores are expressed as means with 95%CI. We compared mean IBS-QOL score and its subscales among various IBS-subtypes. Analysis of variance (ANOVA) was used to compare the mean difference between more than two groups after controlling for age and gender. A post-hoc analysis using Bonferroni correction was used only when P value for ANOVA was less than 0.05., Results: Of 542 patients screened, 243 had IBS as per Rome-III criteria. IBS-mixed (IBS-M) was the most common IBS subtype (121 patients, 49.8%) followed by IBS- diarrhea (IBS-D) (56 patients, 23.1%), IBS-constipation (IBS-C) (54 patients, 22.2%) and IBS-unspecified (IBS-U) (12 patients, 4.9%). Overall IBS-QOL scores were significantly different among various IBS-subtypes (P = 0.01). IBS-QOL of patients with IBS-D (61.6, 95%CI: 54.0-69.1) and IBS-M (63.0, 95%CI: 58.1-68.0) was significantly lower than patients with IBS-C (74.5, 95%CI: 66.9-82.1) (P = 0.03 and 0.02 respectively). IBS-D patients scored significantly lower than IBS-C on food avoidance (45.0, 95%CI: 34.8-55.2 vs 61.1, 95%CI: 50.8-71.3, P = 0.04) and interference with activity (59.6, 95%CI: 51.4-67.7 vs 82.3, 95%CI: 74.1-90.6, P < 0.001). IBS-M patients had more interference in their activities (61.6, 95%CI: 56.3-66.9 vs 82.3, 95%CI: 74.1-90.6, P = 0.001) and greater impact on their relationships (73.3, 95%CI: 68.4-78.2 vs 84.7, 95%CI: 77.2-92.2, P = 0.02) than IBS-C patients. Patients with IBS-M also scored significantly lower than IBS-C on food avoidance (47.2, 95%CI: 40.7-53.7 vs 61.1, 95%CI: 50.8-71.3, P = 0.04) and social reaction (66.1, 95%CI: 61.1-71.1 vs 80.0, 95%CI: 72.1-87.7, P = 0.005)., Conclusion: IBS-D and IBS-M patients have lower IBS-QOL than IBS-C patients. Clinicians should recognize food avoidance, effects on daily activities and relationship problems in these patients.

Published
2015
Full Text
View/download PDF

47. The investigational drug camicinal for the treatment of gastroparesis.

Author

Barshop K and Kuo B

Abstract

Introduction: Gastroparesis is a syndrome of delayed gastric emptying in the absence of mechanical obstruction that presents with upper gastrointestinal symptoms. Despite its growing prevalence, there remains an unmet clinical need for more efficacious prokinetic treatment options. The current market includes prokinetic agents that reduce gastroparesis symptoms. However, adverse drug effects and tachyphylaxis with repeated dosing are among the factors that limit their use. Camicinal (GSK962040) is the most advanced, small-molecule, selective motilin receptor agonist with therapeutic potential to date. Areas covered: This article reviews the literature on the limitations of current prokinetic agents used in the treatment of gastroparesis. It also summarizes the current evidence and influential clinical trial results involving the investigational drug camicinal, and shares its preliminary findings from the literature. Expert opinion: Camicinal represents a new opportunity as a treatment in a clinical area in need of new agents. There is emerging literature to support how the drug addresses both gastroparesis symptoms and dysmotility with no significant adverse effects or tachyphylaxis reported to date. Challenges remain in getting a new compound approved for gastroparesis. However, careful design of future trials will help to continue the record of success camicinal trials have had thus far.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results